Search

Your search keyword '"Deconink E"' showing total 6 results
Start Over Author "Deconink E"
6 results on '"Deconink E"'

1. Effect of immune modulation in relapsed peripheral T-cell lymphomas after post-allogeneic stem cell transplantation: a study by the Société Française de Greffe de Moelle et de Thérapie Cellulaire (SFGM-TC)

Author

Mamez, A-C, Lévy, V, Chevallier, P, Blaise, D, Vigouroux, S, Xhaard, A, Fegueux, N, Contentin, N, Beguin, Y, Ifrah, N, Bulabois, C-E, Suarez, F, Yakoub-Agha, I, Turlure, P, Deconink, E, Lamy, T, Cahn, J Y, Huynh, A, Maury, S, Fornecker, L M, Ouzegdouh, M, Bay, J-O, Guillerm, G, Maillard, N, Michallet, M, Malfuson, J-V, Bourhis, J-H, Rialland, F, Oumedaly, R, Jubert, C, Leblond, V, Boubaya, M, Mohty, M, and Nguyen, S

Published
2016
Full Text
View/download PDF

2. EFFECT OF IMMUNOMODULATION FOR PERIPHERAL T-CELL LYMPHOMA IN RELAPSE AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANT:A SFGM-TC STUDY ON 64 PATIENTS: PH-O112

Author

Mamez, A.-C., Levy, V., Chevallier, P., Vigouroux, S., Xhaard, A., Contentin, N., Mohty, M., Yakoub-Agha, I., Bulabois, C. E., Deconink, E., Lamy, T., huynh, A., Fegueux, N., Turlure, P., Maury, S., Beguin, Y., Bourhis, J.-H., Bilger, K., Bay, J.-O., Guillerm, G., Suarez, F., Maillard, N., Rialland, F., Jubert, C., and Quoc, Nguyen S.

Published
2014

3. Effect of immune modulation in relapsed peripheral T-cell lymphomas after post-allogeneic stem cell transplantation: a study by the Société Française de Greffe de Moelle et de Thérapie Cellulaire (SFGM-TC)

Author

Mamez, A-C, primary, Lévy, V, additional, Chevallier, P, additional, Blaise, D, additional, Vigouroux, S, additional, Xhaard, A, additional, Fegueux, N, additional, Contentin, N, additional, Beguin, Y, additional, Ifrah, N, additional, Bulabois, C-E, additional, Suarez, F, additional, Yakoub-Agha, I, additional, Turlure, P, additional, Deconink, E, additional, Lamy, T, additional, Cahn, J Y, additional, Huynh, A, additional, Maury, S, additional, Fornecker, L M, additional, Ouzegdouh, M, additional, Bay, J-O, additional, Guillerm, G, additional, Maillard, N, additional, Michallet, M, additional, Malfuson, J-V, additional, Bourhis, J-H, additional, Rialland, F, additional, Oumedaly, R, additional, Jubert, C, additional, Leblond, V, additional, Boubaya, M, additional, Mohty, M, additional, and Nguyen, S, additional

Published
2015
Full Text
View/download PDF

4. Autologous stem cell transplantation for progressive multiple sclerosis: Update of the European Group for Blood and Marrow Transplantation autoimmune diseases working party database.

Author

Saccardi, R., Kozak, T., Bocelli-Tyndall, C., Fassas, A., Kazis, A., Havrdova, E., Carreras, E., Saiz, A., Löwenberg, B., te Boekhorst, P. A. W., Gualandi, F., Openshaw, H., Longo, G., Pagliai, F., Massacesi, L., Deconink, E., Ouyang, J., Nagore, F..J. Z., Besalduch, J., and Lisukov, I. A.

Subjects
HEMATOPOIETIC stem cell transplantation, AUTOTRANSPLANTATION, AUTOIMMUNE disease treatment, MULTIPLE sclerosis, IMMUNOSUPPRESSION, NEUROLOGIC examination, PATIENTS
Abstract

Over the last decade, hematopoietic stem cells transplantation (HSCT) has been increasingly used in the treatment of severe progressive autoimmune diseases. We report a retrospective survey of 183 multiple sclerosis (MS) patients, recorded in the database of the European Blood and Marrow Transplantation Group (EBMT). Transplant data were available from 178 patients who received an autologous graft. Overall, transplant related mortality (TRM) was 5.3% and was restricted to the period 1995–2000, with no further TRM reported since then. Busulphan-based regimens were significantly associated with TRM. Clinical status at the time of transplant and transplant techniques showed some correlations with toxicity. No toxic deaths were reported among the 53 patients treated with the BEAM (carmustine, etoposide, cytosine-arabinoside, melphalan)/antithymocyte globulin (ATG) regimen without graft manipulation, irrespective of their clinical condition at the time of the transplant. Improvement or stabilization of neurological conditions occurred in 63% of patients at a median follow-up of 41.7 months, and was not associated with the intensity of the conditioning regimen. In this large series, HSCT was shown as a promising procedure to slow down progression in a subset of patients affected by severe, progressive MS; the safety and feasibility of the procedure can be significantly improved by appropriate patient selection and choice of transplant regimen. [ABSTRACT FROM AUTHOR]

Published
2006
Full Text
View/download PDF

5. Autologous stem cell transplantation for progressive multiple sclerosis: update of the European Group for Blood and Marrow Transplantation autoimmune diseases working party database

Author

Saccardi, R., Kozak, T., Bocelli Tyndall, C., Fassas, A., Kazis, A., Havrdova, E., Carreras, E., Saiz, A., Lowenberg, B., Te Boekhorst, P. A., Gualandio, F., Openshaw, H., Longo, G., Pagliai, F., Massacesi, L., Deconink, E., Ouyang, J., Nagore, F. J., Besalduch, J., Lisukov, I. A., Bonini, A., Merelli, E., Slavino, S., Gratwohl, A., Passweg, J., Tyndall, A., Steck, A. J., Andolina, M., Capobianco, M., Martin, J. L., Alessandra Lugaresi, Meucci, G., Saez, R. A., Clark, R. E., Fernandez, M. N., Fouillard, L., Hernstein, B., Koza, V., Cocco, E., Baurmann, H., Mancardi, G. L., Autoimmune Disease Working Party of EBMT, R. Saccardi, T. Kozak, C. Bocelli-Tyndall, A. Fassa, A Kazi, E. Havrdova, E. Carrera, A. Saiz, B. Lowenberg, P.A. te Boekhorst, F. Gualandio, H. Openshaw, G. Longo, F. Pagliai, L. Massacesi, E. Deconink, J. Ouyang, F.J. Nagore, J. Besalduch, I.A. Lisukov, A. Bonini, E. Merelli, S. Slavino, A. Gratwohl, J. Passweg, A. Tyndall, A.J. Steck, M. Andolina, M. Capobianco, J.L. Martin, A. Lugaresi, G. Meucci, R.A. Saez, R.E. Clark, M.N. Fernandez, L. Fouillard, B. Hernstein, V. Koza, E. Cocco, H. Baurmann, G.L. Mancardi, and Autoimmune Disease Working Party of EBMT

Subjects
surgical procedures, operative, autologous stem cell transplantation, multiple sclerosis, therapy
Abstract

Over the last decade, hematopoietic stem cells transplantation (HSCT) has been increasingly used in the treatment of severe progressive autoimmune diseases. We report a retrospective survey of 183 multiple sclerosis (MS) patients, recorded in the database of the European Blood and Marrow Transplantation Group (EBMT). Transplant data were available from 178 patients who received an autologous graft. Overall, transplant related mortality (TRM) was 5.3% and was restricted to the period 1995-2000, with no further TRM reported since then. Busulphan-based regimens were significantly associated with TRM. Clinical status at the time of transplant and transplant techniques showed some correlations with toxicity. No toxic deaths were reported among the 53 patients treated with the BEAM (carmustine, etoposide, cytosine-arabinoside, melphalan)/antithymocyte globulin (ATG) regimen without graft manipulation, irrespective of their clinical condition at the time of the transplant. Improvement or stabilization of neurological conditions occurred in 63% of patients at a median follow-up of 41.7 months, and was not associated with the intensity of the conditioning regimen. In this large series, HSCT was shown as a promising procedure to slow down progression in a subset of patients affected by severe, progressive MS; the safety and feasibility of the procedure can be significantly improved by appropriate patient selection and choice of transplant regimen.

6. EFFECT OF IMMUNOMODULATION FOR PERIPHERAL T-CELL LYMPHOMA IN RELAPSE AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANT: A SFGM-TC STUDY ON 64 PATIENTS

Author

Mamez, A. C., Levy, V., Chevallier, P., Vigouroux, S., Xhaard, A., Contentin, N., Mohty, M., Ibrahim Yakoub-Agha, Bulabois, C. E., Deconink, E., Lamy, T., Huynh, A., Fegueux, N., Turlure, P., Maury, S., Beguin, Y., Bourhis, J. H., Bilger, K., Bay, J. O., Guillerm, G., Suarez, F., Maillard, N., Rialland, F., Jubert, C., and Quoc, S. N.

Catalog

Books, media, physical & digital resources
See catalog results